Merck is nearing a deal to acquire Cidara, a San Diego-based biotech company that specializes in flu treatment. Cidara's lead drug offers a potential alternative to traditional flu vaccines for vulnerable patients. This acquisition could have a positive impact on Merck's pharmaceutical portfolio.